Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients

European Journal of Haematology

Volumn 67, Issue 4, 2001, Pages 230-231

  Hagège, Isabelle ^a   Becker, Annie ^b   Kerdaffrec, Thierry ^b   Kanfer, Alain ^a   Girot, Robert ^c  

^a Hôpital de Jour de Médecine   (France)

^b Pharmacie   (France)

^c HÔPITAL TENON   (France)

Author keywords

Deferoxamine; Iron overload; Serum ferritin; Thalassemia

Indexed keywords

DEFEROXAMINE; FERRITIN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHELATION THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; THALASSEMIA;

ADULT; BLOOD TRANSFUSION; CHELATING AGENTS; CHELATION THERAPY; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; INFUSION PUMPS; IRON; IRON OVERLOAD; MALE; THALASSEMIA; TREATMENT OUTCOME;

EID: 0035704934     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00386.x     Document Type: Article

References (9)

1. Iron chelating therapy and the treatment of thalassemia
2. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
3. Deferoxamine ototoxicity: Evaluation of risk factors in thalassemic patients and guidelines for safe dosage
4. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload
5. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
6. Current treatment of Cooley's anemia. Intravenous chelation therapy
7. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia
8. Intensification du traitement chélateur du fer par la déféroxamine à l'aide d'une chambre implantable d'accès veineux (Port-A-Cath)
9. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions